|
Market Closed -
Other stock markets
|
After hours 01:00:00 | |||
| 376.04 USD | +1.22% |
|
351.92 | -6.41% |
| 07-24 | Amgen submits new data to challenge FDA's proposal to withdraw Tavneos | RE |
| 07-24 | CuraTeQ Biologics Wins European Medicines Agency's Positive Opinion for Neulasta Biosimilar | MT |
| Market Cap | 203B 178B 166B 152B 286B 19,544B 290B 1,968B 769B 9,609B 762B 745B 33,222B | P/E 2026 * |
24.7x | P/E 2027 * | 22.6x |
|---|---|---|---|---|---|
| Enterprise Value | 245B 215B 200B 183B 345B 23,558B 350B 2,373B 927B 11,582B 918B 899B 40,044B | EV / Sales 2026 * |
6.48x | EV / Sales 2027 * | 6.2x |
| Free-Float |
99.78% | Yield 2026 * |
2.68% | Yield 2027 * | 2.83% |
Last Transcript: Amgen Inc.
| 1 day | +1.22% | ||
| 1 week | +2.66% | ||
| Current month | +3.84% | ||
| 1 month | +7.00% | ||
| 3 months | +9.14% | ||
| 6 months | +9.08% | ||
| Current year | +14.89% |
| 1 week | 359.21 |  | 379.41 |
| 1 month | 353.95 | | 379.41 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 228.21 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 30/04/2012 |
| Director of Finance/CFO | 62 | 12/05/2010 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 31/12/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 31/12/2012 |
Tyler Jacks
BRD | Director/Board Member | 65 | 31/12/2011 |
Robert Eckert
BRD | Director/Board Member | 71 | 31/12/2011 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/05/26 | Free | Director | 665 | 0.0001% | ||
| 19/05/26 | Free | Director | 665 | 0.0001% | ||
| 19/05/26 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | |
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | |
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | |
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| -0.16% | -2.04% | -3.20% | -34.58% | 143B | |
| Average | +0.31% | +0.93% | +23.02% | +43.26% | 375.65B | |
| Weighted average by Cap. | +0.51% | +1.77% | +34.26% | +73.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.76B 33.16B 30.84B 28.3B 53.17B 3,636B 53.99B 366B 143B 1,788B 142B 139B 6,181B | 38.69B 33.98B 31.6B 29B 54.49B 3,726B 55.33B 375B 147B 1,832B 145B 142B 6,333B |
| Net income | 8.22B 7.22B 6.71B 6.16B 11.57B 792B 11.75B 79.72B 31.15B 389B 30.85B 30.19B 1,345B | 8.85B 7.77B 7.23B 6.63B 12.46B 852B 12.66B 85.85B 33.54B 419B 33.23B 32.51B 1,449B |
| Net Debt | 41.67B 36.6B 34.04B 31.23B 58.69B 4,013B 59.59B 404B 158B 1,973B 156B 153B 6,822B | 36.76B 32.29B 30.03B 27.55B 51.77B 3,540B 52.57B 357B 139B 1,740B 138B 135B 6,017B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | US$376.04 | +1.22% | 2,493,755 |
| 23/07/26 | US$371.50 | +1.49% | 2,931,905 |
| 22/07/26 | US$366.05 | -0.05% | 1,548,450 |
| 21/07/26 | US$366.24 | +0.57% | 2,881,907 |
| 20/07/26 | US$364.17 | -0.58% | 1,922,161 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
